Sequence variants of peroxisome proliferator-activated receptor-gamma gene and the clinical courses of patients with end-stage renal disease

Disease Markers

Volumn 2015, Issue , 2015, Pages

  Chao, Chia Ter ^a,b   Chen, Yen Ching ^b   Chiang, Chih Kang ^a,b   Huang, Jenq Wen ^a   Hu, Fu Chang ^b   Fang, Cheng Chung ^a   Chang, Chen Chih ^a   Yen, Chung Jen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; HEMOGLOBIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CHRONIC GLOMERULONEPHRITIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY POLYCYSTIC DISEASE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; GENETICS; MISSENSE MUTATION; PATHOLOGY;

AGED; CASE-CONTROL STUDIES; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MUTATION, MISSENSE; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA;

EID: 84924236401     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2015/763459     Document Type: Article

References (35)

1. A. S. Levey, A. C. Schoolwerth, N. R. Burrows, D. E. Williams, K. R. Stith, and W. McClellan, "Comprehensive public health strategies for preventing the development, progression, and complications of CKD: report of an expert panel convened by the Centers for Disease Control and Prevention," The American Journal of Kidney Diseases, vol. 53, no. 3, pp. 522-535, 2009.
2. S. Moeller, S. Gioberge, and G. Brown, "ESRDpatients in 2001: global overview of patients, treatment modalities and development trends,"NephrologyDialysis Transplantation, vol. 17,no. 12, pp. 2071-2076, 2002.
3. W.-C. Yang and S.-J. Hwang, "Incidence, prevalence and mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to 2001: the impact of national health insurance," NephrologyDialysis Transplantation, vol. 23,no. 12,pp. 3977-3982, 2008.
4. KDOQI, "KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease," The American Journal of Kidney Diseases, vol. 49, no. 2, supplement 2, pp. S12-S154, 2007.
5. R. T. Gansevoort, F. L. Nauta, and S. J. L. Bakker, "Albuminuria: all you need to predict outcomes in chronic kidney disease?" Current Opinion in Nephrology and Hypertension, vol. 19, no. 6, pp. 513-518, 2010.
6. H. Yki-Järvinen, "Thiazolidinediones," The New England Journal of Medicine, vol. 351, no. 11, pp. 1106-1118, 2004.
7. B. P. Kota, T. H. Huang, and B. D. Roufogalis, "An overview on biologicalmechanisms of PPARγs," Pharmacological Research, vol. 51, no. 2, pp. 85-94, 2005.
8. W. Wahli and L. Michalik, "PPARγs at the crossroads of lipid signaling and inflammation," Trends in Endocrinology and Metabolism, vol. 23, no. 7, pp. 351-363, 2012.
9. J. Song, M. Sakatsume, I. Narita et al., "Peroxisome proliferatoractivated receptor gamma C161T polymorphisms and survival of Japanese patients with immunoglobulin A nephropathy," Clinical Genetics, vol. 64, no. 5, pp. 398-403, 2003.
10. A. Szanto and L. Nagy, "The many faces of PPARγ: anti-inflammatory by any means?" Immunobiology, vol. 213, no. 9-10, pp. 789-803, 2008.
11. A. Sugawara, A. Uruno, M. Kudo, K. Matsuda, C.W. Yang, and S. Ito, "Effects of PPARγ on hypertension, atherosclerosis, and chronic kidney disease," Endocrine Journal, vol. 57, no. 10, pp. 847-852, 2010.
12. C. M. Avesani, J. J. Carrero, J. Axelsson, A. R. Qureshi, B. Lindholm, and P. Stenvinkel, "Inflammation and wasting in chronic kidney disease: partners in crime," Kidney International, vol. 70, no. S104, pp. S8-S13, 2006.
13. S. S.Deeb, L. Fajas, M.Nemoto et al., "APro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity," Nature Genetics, vol. 20, no. 3, pp. 284-287, 1998.
14. S. de Cosmo, N. Motterlini, S. Prudente et al., "Impact of the PPARγ-2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence fromBENEDICT," Diabetes, vol. 58,no. 12,pp. 2920-2929, 2009.
15. N.Wang, R. Yin, Y. Liu, G.Mao, and F. Xi, "Role of peroxisome proliferator-activated receptor-gamma in atherosclerosis: an update," Circulation Journal, vol. 75, no. 3, pp. 528-535, 2011.
16. H. Zhang, S. Zhu, J. Chen et al., "Peroxisome proliferator-activated receptor polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies," Diabetes Care, vol. 35, no. 6, pp. 1388-1393, 2012.
17. C.-J. Yen, B. A. Beamer, C. Negri et al., "Molecular scanning of the human peroxisome proliferator activated receptor γ (hPPARγ) gene in diabetic Caucasians: identification of a Pro12Ala PPARγ2 missense mutation," Biochemical and Biophysical Research Communications, vol. 241, no. 2, pp. 270-274, 1997.
18. Z. Yang, J. Wen, Q. Li et al., "PPARγG gene Pro12Ala variant contributes to the development of non-alcoholic fatty liver in middle-aged and older Chinese population," Molecular and Cellular Endocrinology, vol. 348, no. 1, pp. 255-259, 2012.
19. J. Prakash,N. Srivastava, S.Awasthi et al., "Association of PPARγ-γ gene polymorphisms with obesity and obesity-associated phenotypes in north indian population," American Journal of Human Biology, vol. 24, no. 4, pp. 454-459, 2012.
20. J. S. K. Ho, S. Germer, C. H. T. Tam et al., "Association of the PPARγG Pro12Ala polymorphism with type 2 diabetes and incident coronary heart disease in a Hong Kong Chinese population," Diabetes Research and Clinical Practice, vol. 97, no. 3, pp. 483-491, 2012.
21. H. Zhang,Y. Bi, C. Hu, W. Lu, and D. Zhu, "Associationbetween the Pro12Ala polymorphismof PPARγ-γ gene and the polycystic ovary syndrome: ameta-analysis of case-control studies," Gene, vol. 503, no. 1, pp. 12-17, 2012.
22. Z. F. Zhang, N. Yang, G. Zhao, L. Zhu, and L. X. Wang, "Association between the Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma 2 and inflammatory bowel disease: a meta-analysis," PLoS ONE, vol. 7, no. 1, Article ID e30551, 2012.
23. K. Sanada, M. Iemitsu, H. Murakami et al., "PPARγ2 C1431T genotype increasesmetabolic syndrome risk in youngmen with low cardiorespiratory fitness," Physiological Genomics, vol. 43, no. 3, pp. 103-109, 2011.
24. Z.Wu, Y. Lou, W. Jin,Y. Liu, L. Lu, andG. Lu, "TheC161T polymorphism in the peroxisome proliferator-activated receptor gamma gene (PPARγ) is associated with risk of coronary artery disease: ameta-analysis,"Molecular Biology Reports, vol. 40, no. 4, pp. 3101-3112, 2013.
25. X.-L. Liu, H.-L. Zhao, G.-M. Shen et al., "Analysis of two sequence variants in peroxisome proliferator-activated receptor gamma gene in a Tibetan population at high altitude and a han population at low altitude in China," Medical Science Monitor, vol. 16, no. 10, pp. CR458-CR463, 2010.
26. A. Jorsal, L. Tarnow, M. Lajer et al., "The PPARγ gamma 2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy," Molecular Genetics and Metabolism, vol. 94, no. 3, pp. 347-351, 2008.
27. Q. Yao, L. Nordfors, J. Axelsson et al., "Peroxisome proliferatoractivated receptor γ polymorphisms affect systemic inflammation and survival in end-stage renal disease patients starting renal replacement therapy," Atherosclerosis, vol. 182, no. 1, pp. 105-111, 2005.
28. S. P. Bhatt, A. Misra, M. Sharma et al., "Ala/Ala genotype of Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-γ2 gene is associated with obesity and insulin resistance in Asian Indians," Diabetes Technology andTherapeutics, vol. 14, no. 9, pp. 828-834, 2012.
29. F.Mallamaci andG. Tripepi, "Obesity and ckd progression: hard facts on fat ckd patients," Nephrology Dialysis Transplantation, vol. 28, no. 4, pp. iv105-iv108, 2013.
30. C.-T. Chao, V.-C. Wu, H.-B. Tsai et al., "Impact of body mass on outcomes of geriatric postoperative acute kidney injury patients," Shock, vol. 41, no. 5, pp. 400-405, 2014.
31. W. Xu, Y. Li, X. Wang et al., "PPARγ polymorphisms and cancer risk: a meta-analysis involving 32,138 subjects," Oncology Reports, vol. 24, no. 2, pp. 579-585, 2010.
32. D. K. Sanghera, F. Y. Demirci, L. Been et al., "PPARγG and ADIPOQgene polymorphisms increase type 2 diabetes mellitus risk in Asian Indian Sikhs: Pro12Ala still remains as the strongest predictor,"Metabolism: Clinical and Experimental, vol. 59, no. 4, pp. 492-501, 2010.
33. B.Mao, J. Zhang, and F. Zhuo, "MCP-1-2518A>Gpolymorphism and myocardial infarction risk: a meta-analysis and metaregression," Genetic Testing and Molecular Biomarkers, vol. 17, no. 12, pp. 857-863, 2013.
34. W. Fan,W.Maoqing, C.Wangyang et al., "Relationship between the polymorphism of tumor necrosis factor-[alpha]-308 G > A and susceptibility to inflammatory bowel diseases and col orectal cancer: a meta-analysis," European Journal of Human Genetics, vol. 19, no. 4, pp. 432-437, 2011.
35. C.-C. Szeto, K.-M. Chow, P. Y.-K. Poon, B. C.-H. Kwan, and P. K.-T. Li, "Peroxisome proliferator-activated receptor-gamma gene polymorphism and risk of cardiovascular disease in patients with diabetic nephropathy," American Journal of Nephrology, vol. 28, no. 5, pp. 715-722, 2008.